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Background: As benzodiazepines (BZDs) have anxiolytic effects, it
is expected that they influence the stress system. During short-term
treatment, BZD use was found to suppress cortisol levels. However, little
research has been done on the effects of long-term BZD administration
on the hypothalamic-pituitary-adrenal (HPA) axis.
Methods: The association between long-term BZD use and cortisol
levels was investigated in subjects of the Netherlands Study of De-
pression and Anxiety with a lifetime diagnosis of anxiety or depression
(n = 1531). The subjects were categorized as Bdaily BZD users[ (n = 96),
Binfrequent BZD users[ (n = 172), and Bnonusers[ (n = 1263). Possible
associations between characteristics of BZD use (dose, duration, and
dependence) and salivary cortisol levels were analyzed.
Main Outcome Measure: Subjects provided 7 saliva samples, from
which 4 cortisol indicators were calculated: the cortisol awakening re-
sponse, diurnal slope, evening cortisol, and cortisol suppression after
ingestion of 0.5 mg of dexamethasone.
Results: Daily users used BZDs for a median duration of 26.5 months
and had a median daily dosage of 6.0 mg as measured in diazepam
equivalents. Evening cortisol levels were significantly lower in daily
users (P = 0.004; effect size: d = 0.24) and infrequent users (P = 0.04;
effect size: d = 0.12) compared to nonusers. We did not find significant
differences in the cortisol awakening response, diurnal slope, or in the
dexamethasone suppression test.
Conclusions: Despite the finding of slightly lower evening cortisol
levels in daily and infrequent BZD users compared to nonusers, results
indicate that long-term BZD use is not convincingly associated with
HPA axis alterations.
Key Words: benzodiazepines, anxiolytics, cortisol, HPA axis,
long-term use
Abbreviations: BZD - benzodiazepines,
HPA axis - hypothalamic-pituitary-adrenal axis, CAR - cortisol
awakening response, DST - dexamethasone suppression test
(J Clin Psychopharmacol 2010;30: 160Y168)
A s benzodiazepines (BZDs) have anxiolytic and sedatingeffects, it is expected that they influence the stress system.
Most studies on the effects of short-term BZD treatment
(maximum of 3 months) on the hypothalamic-pituitary-adrenal
(HPA) axis in human subjects reported a decrease in cortisol
levels,1Y11 although some studies reported mixed results.12,13
These inconsistencies may be explained by differences in dos-
ages and half-lives of the BZDs used13 and by disparities in the
time points used in the assessments (only predrug and post-
drug measurements,13 at certain time intervals,6,8,10Y12,14 or for a
full circadian cycle1,2,5). Differences in patient groups,12,13 and
measurements of basal versus stress-provoked cortisol levels
may also influence the results.3,13 In general, the studies mea-
sured plasma cortisol levels1Y3,5,6,9,11,13 or urinary free cortisol
as measures of HPA axis activity.4 Associations between BZD
use and dexamethasone suppression have only been investi-
gated in 1 study and no clear effect of BZD use on dexametha-
sone suppression was observed.14 A few studies found that the
cortisol decrease in response to BZD treatment was followed
by a return to baseline cortisol levels within only a few hours,
despite persisting high plasma drug levels,15Y17 suggesting fast
development of tolerance to the stress axisYsuppressing effects
of BZDs. In contrast, other studies did report significant cor-
tisol reductions in 24-hour, overnight, and daytime means,1 sug-
gesting that tolerance does not develop as rapidly.
Tolerance to the effects of BZDs as a consequence of
chronic use (93 months) has been extensively discussed in pre-
vious studies.18,19 In related research on the therapeutic effects
of BZDs, several authors reported that tolerance was developed
to only the cognitive and psychomotor effects and not to the
anxiolytic effects of chronic BZD treatment,19 whereas others
found decreasing anxiolytic efficacy as well when treatment
exceeded a few weeks.18 Most studies on the effects of BZDs
on cortisol levels found that cortisol suppression was main-
tained for up to 3 months of use.1,2,4,9,12
There was only 1 small cross-sectional study investigating
long-term BZD use (93 months).20 The authors found that long-
term users have similar baseline cortisol levels as nonusers,
indicating that BZDs do not maintain their cortisol-suppressing
effects during longer-term use. In contrast, an additional dosage
of BZDs (on top of the BZD dosage that long-term users took
in the morning) still affected the HPA axis after chronic use.
However, comparison groups were small, no measurement of
the whole circadian rhythm was conducted, and no dexametha-
sone challenge test was applied.20
In this paper, we examine the effects of chronic BZD use on
various salivary cortisol measures (cortisol awakening response,
diurnal slope, evening cortisol level, and suppression after oral
dexamethasone administration). In addition, we explore the ef-
fects of dosage, duration of use, and level of dependence. The
study was carried out on data from 1531 subjects with a life-
time diagnosis of anxiety and/or depression participating in the
Netherlands Study of Depression and Anxiety (NESDA).
MATERIALS AND METHODS
Subjects
Subjects participated in the baseline assessment of the
NESDA, an 8-year longitudinal cohort study of 2981 respon-
dents aged 18 to 65 years.21 Subjects were recruited from the
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community, general practice, and specialized mental health care
institutions throughout the Netherlands. Subjects completed a
medical examination, an in-person interview, saliva collection,
and several questionnaires. The study protocol was approved
by the ethical review board of each participating center, and all
subjects signed an informed consent at the baseline assessment.
To investigate the associations between BZD use and sali-
vary cortisol indicators, 3 groups were defined: subjects who
reported daily BZD use in the month before the baseline inter-
view (Bdaily BZD users,[ n = 176), subjects who used BZDs
on an infrequent basis in the previous month (Binfrequent BZD
users[, n = 264) and those reporting no use of BZDs in the last
month (Bnonusers,[ n = 1854). All subjects reported a current
or past diagnosis of a depressive or anxiety disorder (referred
to as a lifetime disorder), defined as an anxiety disorder (panic
disorder with or without agoraphobia, generalized anxiety dis-
order, or social phobia) or depressive disorder (dysthymia or
major depressive disorder [MDD]) as assessed by the Composite
International Diagnostic Interview (WHO version 2.1) which
classifies diagnoses according to the criteria of the Diagnostic
and Statistic Manual of Mental Disorders IV-TR (American
Psychiatric Association, 2001). From these 3 groups, 1664
(72.5%) subjects returned saliva samples. Responders on saliva
collection did not differ from nonresponders in sex (67.7% vs
68.3% women; P = 0.79) but were older (43.6 T 12.5 years vs
37.9 T 11.9 years; P G 0.001), more educated (12.2 T 3.3 years
vs 11.5 T 3.2 years; P G 0.001), and less likely to have a lifetime
diagnosis of comorbid disorder (55.5% vs 64.0%; P G 0.001).
Furthermore, responders had marginally significantly lower rates
of BZD use (18.2% vs 21.7%; P = 0.06). Of the responders,
1658 provided sufficient cortisol samples of high quality from
which at least 1 usable salivary cortisol indicator (cortisol awak-
ening response [CAR], diurnal slope, evening cortisol, or dexa-
methasone suppression test [DST]; see later section) could be
calculated.
Because of known associations with cortisol or use of
BZDs for conditions other than anxiety or depression, pregnant
or breastfeeding women (n = 10), subjects using corticosteroids
(n = 104), and patients with epilepsy (n = 13) were excluded,
leaving a final sample of 1531 subjects (1263 nonusers, 172
infrequent BZD users, and 96 daily BZD users).
Measures
Benzodiazepine Use
Four indicators of BZD use were investigated: type of BZD,
daily BZD dose, duration of BZD use, and BZD dependence
severity. BZD use during the month before baseline interview
was registered by observation of drug containers brought to the
interview (73.4%) or self-report (26.6%). Daily and infrequent
BZD users reported the type and dosage of BZD taken on an
average day of use. Frequency of use for infrequent users was
taken into account when calculating the average daily dose. The
daily BZD dose was computed according to the coding system
of the Anatomical Therapeutic Code (ATC) and defined daily
dose (DDD) system.22 The mean daily dose was calculated by
dividing individual daily doses (in milligrams) of BZDs by the
DDD for the particular BZD. Benzodiazepines were classified as
ATC-coded groups N05BA, N05CD, and N03AE01. The non-
BZD hypnotics zopiclone and zolpidem (ATC code N05CF)
were also included. Similar to BZDs, these hypnotics act on the
central omega I gamma aminobutyric acid receptor. For patients
using BZDs other than diazepam, an equivalent daily dose was
calculated with conversion tables,23,24 and 10mg of diazepamwas
regarded equivalent to 1 mg of alprazolam, 10 mg of broma-
zepam, 0.25 mg of brotizolam, 20 mg of clobazam, 20 mg of
chlordiazepoxide, 13.3 mg of clorazepate, 8 mg of clonazepam,
30 mg of flurazepam, 1 mg of loprazolam, 2 mg of lorazepam,
1 mg of lormetazepam, 7.5 mg of midazolam, 10 mg of nitra-
zepam, 33 mg of oxazepam, 20 mg of prazepam, 20 mg of tema-
zepam, 20 mg of zolpidem, and 13 mg of zopiclone. Dosages
were summed when more than 1 BZD was used. The duration of
BZD use was reported in months. Benzodiazepine users com-
pleted the Benzodiazepine Dependence Self-Report Question-
naire (Bendep-SRQ), a 15-item self-report questionnaire, as a
measure of dependence severity. Each item was rated on a 5-
point scale. Three dependence dimensions were derived: (1)
awareness of problematic use, (2) preoccupation with the avail-
ability of benzodiazepines, and (3) lack of compliance with the
therapeutic regimen.25 The Bendep-SRQ has good scalability,
reliability, and validity in general practice patients26 and in psy-
chiatric outpatients.27
Salivary Cortisol
The respondents were asked to collect saliva samples at
home on a regular, preferably working day shortly after the
baseline interview by using Salivettes (Sarstedt AG and Co,
Nürmbrecht, Germany).28 The median time between the interview
and saliva sampling was 9 days (25thY75th percentile: 4Y22).
Eating, smoking, drinking tea or coffee, or brushing teeth was
prohibited within 15 minutes of sampling. Saliva was measured
at 7 time points (Ts): upon awakening (T1), 30 minutes (T2), 45
minutes (T3), and 60 minutes (T4) after awakening and in the
evening at 10 PM (T5) and 11 PM (T6). Immediately after saliva
sampling at T6, the cortisol suppression testwas carried out by oral
administration of a 0.5-mg dexamethasone pill and assessed by
cortisol sampling the next morning directly after awakening (T7).
All samples were refrigerated and returned by mail. During
laboratory analysis, Salivettes were centrifuged at 2000g for
10 minutes, aliquoted, and stored atj80-C. Competitive electro-
chemiluminescence immunoassay (E170, Roche, Basel, Switzer-
land) was used to measure cortisol levels at a functional detection
limit of 2.0 nmol/l.29 Intra-assay and interassay variability
coefficients in the measuring range were less than 10%. Assays
were repeated if cortisol levels were very high (980 nmol/L) or
very low (G1 nmol/L) (n = 128). All very high samples remained
high in the second measurement, and the mean of the 2 measured
values was used in further analyses. In 80% of the very low
samples, the repeated cortisol valuewas within the reference range
and was used for analysis. In cases where the second measurement
was also very low, the mean of the samples was used. Data
cleaning was performed by excluding cortisol values more than 2
SDs above the mean.28
Four cortisol measures were derived: the CAR, diurnal
slope, evening cortisol, and cortisol suppression on the DST.28
Cortisol Awakening Response (CAR)
The CAR was calculated from 4 sampling points: T1, T2,
T3, and T4. In our study, it was calculated by analysis of T1 to
T4 with linear mixed models (LMM) and 2 aggregate indicators:
area under the curve with respect to the ground (AUCg) and
with respect to the increase (AUCi) according to Pruessner’s
formulas.30 The AUCg is an estimate of the total cortisol secre-
tion and predicts mean cortisol levels throughout the day, and
the AUCi is a measure of the dynamics of the CAR, related to
the sensitivity of the system and emphasizing changes over
time.28,30 For the AUC analyses, a minimum of 3 samples were
required. For those with 1 missing cortisol value (n = 84),
the fourth was imputed using linear regression analyses with
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information on the other available 3 cortisol values, sex, age,
awakening time, and smoking status.
Diurnal Slope and Evening Cortisol
As cortisol levels at 10 PM (T5) and 11 PM (T6) were
correlated (r = 0.73, P G 0.01), evening cortisol was defined as
the average of the 2 values (T5 and T6) or by one of the 2 if only
one was available. Diurnal slope was calculated by subtracting
the evening cortisol level (as calculated earlier) from the cortisol
level at T1 and dividing it by the time in hours between the 2
samples, resulting in the change over time of cortisol through-
out the day, calculated per hour.28,31
Dexamethasone Suppression Test (DST)
In addition to the cortisol level at awakening after dexa-
methasone ingestion (T7), a cortisol suppression ratio was
calculated by dividing the cortisol value at awakening on day
1 (T1) by the post-dexamethasone cortisol value at awakening
TABLE 1. Characteristics of Study Groups
N
Nonusers Infrequent Users Daily Users
Pn = 1263 n = 172 n = 96
Sociodemographics
Sex, % female 1531 67.2 71.5 58.3 0.09
Age, yrs 1531 42.5 (41.9Y43.2) 46.0 (44.2Y47.9) 48.6 (46.2Y51.1) G0.001
Education level, yrs 1531 12.3 (12.1Y12.5) 12.0 (11.5Y12.5) 11.3 (10.6Y11.9) 0.009
North European ancestry, % 1531 95.1 93.0 96.9 0.34
Sampling characteristics
Time of awakening 1531 7.27 h (7.23Y7.31 h) 7.40 h (7.28Y7.52 h) 7.39 h (7.24Y7.53 h) 0.05
Working on day of sampling, % 1531 63.2 50.6 33.3 G0.001
Sampling on a weekday, % 1531 92.8 86.0 86.5 0.002
Sampling in month with more daylight hours, % 1531 56.4 64.0 47.9 0.03
e6 hours of sleep, % 1531 27.6 41.3 41.7 G0.001
Health indicators
Smoking, % 1531 36.1 35.5 40.6 0.65
Physical activity (1000 MET min/wk) 1531 3.7 (3.5Y3.9) 3.5 (3.1Y4.0) 3.1 (2.5Y3.7) 0.13
Psychiatric indicators
Lifetime diagnosis, %
MDD only 1531 31.0 23.8 24.0 0.07
Anxiety only 1531 15.4 12.2 9.4 0.18
Comorbid disorder 1531 53.7 64.0 66.7 0.003
Benzodiazepine (BZD) use
Duration of BZD use, mo. 268 N/A 36.0 (5.0Y99.0) 26.5 (5.3Y96.0) 0.29
Daily dosage of BZD (diazepam equivalents, mg)* 268 N/A 1.0 (0.2Y2.0) 6.0 (3.2Y13.9) G0.001
Type of BZD
Oxazepam 1531 N/A 48.8 36.5 G0.001
Temazepam 1531 N/A 24.4 14.6 G0.001
Diazepam 1531 N/A 13.4 10.4 G0.001
Alprazolam 1531 N/A 2.3 14.6 G0.001
Others 1531 N/A 19.2 45.8 G0.001
Bendep SRQ
Highly problematic use 232 N/A 8.0 (6.0Y11.0) 10.0 (8.0Y12.0) G0.001
High preoccupation 232 N/A 12.0 (9.0Y14.0) 15.0 (13.0Y17.0) G0.001
High lack of compliance 232 N/A 6.0 (5.0Y8.0) 8.0 (6.0Y10.0) G0.001
Antidepressant use, %
SSRI 1525 17.6 29.1 44.8 G0.001
TCA 1530 2.7 5.2 7.3 0.02
Others 1528 6.0 10.5 16.7 G0.001
Means (95% confidence intervals [CI]) are given for age, education, time of awakening, physical activity. Median (interquartile range) is given for
duration of BZD use, daily dosage of BZD use, and BENDEP-SRQ, as these values are not normally distributed. Percentages are given for categorical
variables. P is derived by analysis of variance (ANOVA) for quantitative, normally distributed variables, Mann-Whitney U test for continuous, non-
normally distributed variables, or W2 statistics for categorical variables. Significance is inferred at P G 0.05.
*Users reported the dosage of BZDs taken on an average day of use. Frequency of use has been taken into account for infrequent users.
BENDEP-SRQ indicates Benzodiazepine Dependence Self-Report Questionnaire; MDD, major depressive disorder; MET, metabolic equivalent of
number of calories spent per average minute; N/A, not applicable; SSRI, selective serotonin reuptake inhibitor; T, time point; TCA, tricyclic
antidepressant.
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on day 2 (T7). Lower post-dexamethasone cortisol levels
(T7) and higher DST ratios (ie, a larger difference between
T1 and T7) indicate a greater cortisol-suppressing effect of
dexamethasone.
Covariates
As associations between sociodemographics (sex, age, edu-
cation, and North European ancestry), sampling factors (awaken-
ing time, work status, weekday, season, and sleep duration), and
health indicators (smoking, physical activity) on salivary cortisol
variables have been described previously,32 these identified deter-
minants were considered as covariates.
Comorbidity of anxiety and depression as well as anti-
depressant use have been found to be associated with salivary
cortisol levels in previous research in this study sample,28 and
numbers of antidepressant use and comorbidity differed be-
tween BZD groups (Table 1). Therefore, comorbidity and anti-
depressant use were also included as covariates. Depression and
anxiety disorders were established with the Composite Inter-
national Diagnostic Interview (WHO version 2.1), which clas-
sifies diagnoses according to the criteria of the Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition-Text
Revision (American Psychiatric Association, 2001). The use of
antidepressants in the past month was determined by observation
of drug containers brought to the baseline interview. Anti-
depressants were subdivided into selective serotonin reuptake
inhibitors (SSRI, ATC code N06AB), tricyclic antidepressants
(TCA, ATC code N06AA), and other antidepressants (mono-
amine oxidase inhibitors N06AG, nonselective N06AF, and
antidepressants classified as N06AX).
Respondents were asked to report the time of awakening
and working status on the sampling day. Sampling date informa-
tion was used to categorize weekday versus weekend day and
season categorized in less daylight (October through February)
and more daylight (March through September) months. Average
sleep duration during the last week was dichotomized as e6
or 96 hours/night, and smoking status as current versus non-
smoker. Physical activity was assessed using the International
Physical Activity Questionnaire and expressed as activity per
1000 MET-minutes (metabolic equivalent of the number of calo-
ries spent by a person per average minute) a week.28
Statistical Analyses
Characteristics of study groups were expressed by fre-
quencies, means, or medians and compared using W2 statistics
(categorical variables), analysis of variance (continuous vari-
ables, normally distributed), and the Mann-Whitney U test
(continuous variables, non-normally distributed). Area under the
curve with respect to increase and diurnal slope were normally
distributed, which allowed data analysis with nontransformed
values. T1-T4, AUCg, evening cortisol, T7, and DST were
naturally log transformed because of their positively skewed
distributions. Back-transformed values are given in Table 2.
Differences in AUCg, AUCi, diurnal slope, evening cor-
tisol, T7, and DSTacross groups were analyzed using analysis of
covariance (ANCOVA), adjusting for basic sociodemographic
variables, sampling factors, health indicators, comorbidity, and
antidepressant use. Cohen’s d (the difference in group means
divided by their pooled SD) was calculated as a measure of
effect size. Further analysis of the CAR was carried out with
random coefficient analysis of the 4 morning cortisol data
points by using LMM. This analysis keeps original values on all
4 data points, accommodates for missing data, and takes cor-
relations between repeated measurements within subjects into
account.33
Linear regression analyses were used to assess associations
between characteristics of BZD use (ie, duration, dose, and ad-
diction as separate independent variables) and salivary cortisol
indicators as continuous dependent variables after full adjust-
ment in daily and infrequent BZD users.
Differences across the 4 most commonly used benzodi-
azepine types, that is, oxazepam (n = 115), diazepam (n = 33),
alprazolam (n = 16), and temazepam (n = 45) on salivary corti-
sol indicators were analyzed in pairwise comparisons using
ANCOVA, adjusting for the aforementioned covariates. The
other BZDs were not included in these analyses, as group num-
bers were to small (n G 15). Oxazepam was used as the refer-
ence group. Statistical significance was inferred at P G 0.05. All
statistical analyses were conducted using SPSS for Windows,
version 16.0 (SPSS, Chicago, Ill).
RESULTS
Characteristics of the 3 BZD user groups are presented
in Table 1. Benzodiazepine users were older, less educated, more
often diagnosed with a comorbid disorder, and more likely to use
antidepressants compared to nonusers. Only 17.9% of subjects
were short-term users (e3 months), and the remaining 82.1%
were long-term users (93 months). The median duration of use
was 35.5 months (25thY75th percentile: 5Y96). Although the
group of short-term users was too small (n = 48) to be analyzed
separately, exclusion of these subjects did not affect our main
results (data not shown). The median daily dosage of BZDs
used was 1.0 mg (25thY75th percentile: 0.2Y2.0) of diazepam
equivalents for infrequent users and 6.0 mg (25thY75th per-
centile: 3.2Y13.9) of diazepam equivalents for daily users. Crude
saliva levels (T1-T4 and T7) did not differ between groups
(Table 2).
Cortisol Awakening Response
Overall, 71.5% of respondents showed an increase in cor-
tisol in the first hour after awakening, with a mean increase of
6.6 nmol/L (or 53.5%). No significant effects were found for
any of the crude CAR analyses (Table 2). Adjusted CAR results
showed that daily users and infrequent users did not differ on
overall cortisol levels from nonusers, reflected by analysis of
AUCg (P = 0.09 for daily users vs nonusers and P = 0.74
for infrequent users vs nonusers; Table 2) and LMM analysis
(daily users vs nonusers, F(1329, 0.097) = 3.07, P = 0.08; and
infrequent users vs nonusers, F(1413, 642) = 0.11, P = 0.74). A
nonsignificant effect on AUCi (daily users vs nonusers, P = 0.99;
infrequent users vs nonusers, P = 0.99; Table 2) and no sig-
nificant group by time interaction in the LMM analysis (daily
users vs nonusers, F(3947, 327) = 0.49, P = 0.69, and infrequent
users vs nonusers, F(4171, 422) = 0.92, P = 0.43) were found,
indicating a similar time course between groups.
Diurnal Slope
No significant effects were found for crude or adjusted
diurnal slope analyses (daily users vs nonusers: P = 0.79).
Evening Cortisol Level
Unadjusted evening cortisol levels did not differ between
groups (Table 2). After adjustment, evening cortisol was sig-
nificantly lower in daily BZD users (P = 0.004; effect size
[Cohen’s d ], 0.24) and infrequent users (P = 0.04; effect size,
0.12) compared to nonusers. Age and SSRI use were the most
important confounders in the fully adjusted model.
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Dexamethasone Suppression Test
The unadjusted cortisol suppression ratio was significantly
lower in daily users compared to nonusers (P = 0.05; effect
size, 0.08; Table 2), which indicates increased nonsuppression
after dexamethasone ingestion in the daily user group. After
adjustment, however, cortisol suppression ratios (P = 0.71) and
T7 levels (P = 0.46) did not differ between groups. Infrequent
users also did not differ from nonusers on either of the cortisol
indicators (P = 0.46 for cortisol suppression ratio and P = 0.31
for T7).
Characteristics of BZD Use
Table 3 reports the results of additional analyses on specific
associations between salivary cortisol levels and characteristics
of BZD use (duration, dose, and severity of BZD dependence as
measured by the Bendep-SRQ) among the combined BZD user
groups (infrequent and daily). For the duration of use, no effect
on any cortisol indicator was found except for a weak negative
association with adjusted T7 cortisol levels after dexametha-
sone ingestion (A = j0.15, P = 0.03), indicating that a longer
duration of BZD use was associated with a somewhat lower
cortisol level after dexamethasone ingestion, that is, stronger
suppression. The daily BZD dose and the 3 subscales of the
Bendep-SRQ (problematic use, preoccupation, and lack of com-
pliance) were not associated with any salivary cortisol indicator.
Pairwise comparisons of the most common BZD types
showed that the temazepam group did not differ from the
oxazepam group on any of the cortisol indicators. However, the
diazepam group had lower diurnal slope levels (P = 0.01) and a
decreased dexamethasone suppression ratio (P = 0.01) com-
pared to oxazepam users. The alprazolam group had a lower
AUCg than the oxazepam group (P =0.007; data not shown).
DISCUSSION
In this study, the relationship between BZD use and
various salivary cortisol measures was studied in NESDA sub-
jects with a lifetime diagnosis of depression and/or anxiety.
With the exception of slightly lower evening cortisol levels in
daily and infrequent BZD users compared with nonusers, the
user groups did not differ on any cortisol indicators after ad-
justment for covariates. Dose, frequency of use, and dependence
were not associated with salivary cortisol levels except of a
correlation of longer duration of use with stronger cortisol sup-
pression after dexamethasone ingestion. As effect sizes found
were small, the clinical relevance of the statistically significant
findings is limited. Further, in the light of the number of tests
conducted, multiple testing may have caused a type 1 error for
evening cortisol in BZD users.
An explanation for the lack of consistent associations
could be that BZDs inhibit the HPA axis during short-term use
and that tolerance to the cortisol-suppressing effect of BZDs
develops after long-term BZD treatment. Correspondingly, in-
tervention studies that found lower cortisol levels in response to
BZD administration mainly looked at short-term effects during
a period ranging from 1 day to 1 month,3,5,6,9,13,34Y37 except for a
few studies with a duration of 2Y3 months.1,2,4 In contrast, long-
term users were found to have similar baseline cortisol levels
as nonusers, also indicating that BZDs do not maintain their
cortisol-suppressing effects in long-term use.20 As our study
mainly consists of long-term users (3-year median duration of
use), the lack of association between BZD use and baseline
cortisol levels agrees with results from the latter study.20
Although tolerance is likely to develop during long-term
use, an additional dosage of BZDs (on top of a regular daily
dosage) still induces HPA axis inhibition. Indeed, Cowley et al20
found that long-term users showed similar decreases in plasma
cortisol after an extra dosage of BZDs as treatment-naive
patients. In related research on the therapeutic effects of BZDs,
an increased dosage of BZDs was found to increase anxiolytic
effects even after more than 10 years of daily use.38
Along with the hypothesis of tolerance development to
the cortisol-suppressing effects of long-term BZD use, there are
several alternative explanations that may account for discrepan-
cies in the findings. First, BZD users may have had enhanced
HPA axis activity before the start of BZD treatment, which was
subsequently normalized by long-term BZD treatment. Indeed,
a significantly higher percentage of daily users compared to
nonusers had a comorbid disorder, which has been found to be
associated with increased cortisol levels in this study popula-
tion.28 Second, it might be that the joint investigation of a
number of different types of BZDs with possibly opposing
effects on the HPA axis has covered effects on cortisol levels.39
We found lower diurnal slope levels and a decreased dexameth-
asone suppression ratio in the diazepam group and a lower
AUCg in the alprazolam group compared to the oxazepam
group, suggesting some evidence for possibly opposing effects
of different BZDs. This corresponds to a former study that
reported BZDs to have either a stimulating or an inhibiting effect
on the HPA axis conditional on the alpha subunit of the GABA
receptor modulated by the drugs.39 However, as comparison
groups were small in NESDA, results have to be replicated in
future research. Third, stronger effects on cortisol levels may be
due to higher dosages. In intervention studies, higher average
dosages were used than in the current study (ie, 12 mg of
diazepam equivalents in intervention studies vs 6 mg
in NESDA). Another explanation for basal cortisol being the
only cortisol measurement differing significantly between BZD
user groups might be that hippocampal mineralocorticoid re-
ceptors (MRs) are more affected by central-acting BZDs than
glucocorticoid receptors (GRs). Because MRs are more occu-
pied at intermediate cortisol concentrations whereas GRs are
not,40 basal evening cortisol might be a probe of MR activity.41
However, because research on GR, MR, and BZDs is still lim-
ited, this assumption deserves further investigation in future
research.
Our study has some limitations. A cross-sectional analysis
was done, which precludes causal inferences or differentiation
between the potential explanations of the lack of group dif-
ferences in salivary cortisol. Because we had to rely on sub-
jects’ self-report on BZD intake, we cannot be completely sure
whether subjects were actually using the medications as pre-
scribed and as they themselves indicated. Noncompliance with
instructions of saliva collection due to the ambulatory setting
could have resulted in measurement error. In addition, because
time of drug intake was not recorded, acute effects of BZD use
could not be assessed. Despite these limitations, our study had
many strong aspects, including a large sample size with clearly
distinct BZD groups primarily composed of long-term users, the
inclusion of multiple cortisol measures indicative of different
aspects of HPA axis activity, the investigation of various char-
acteristics of use and the adjustment for various potential
confounders.
In conclusion, we found no consistent associations be-
tween BZD use and salivary cortisol indicators within a sample
composed primarily of long-term users. This finding is in line
with the hypothesis that the HPA axis develops tolerance to the
cortisol-suppressing effect of BZDs during chronic BZD use.
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